Evidence map›Paper›PMID 41567735›Full record

ArticleMaterials today. Bio2026

Resveratrol-embedded hollow cerium oxide nanomedicine targeted treat inflammatory bowel disease through ROS clearance, intestinal mucosal immune homeostasis recovery and gut microbiota modulation.

Tianlin Wang, Xiaoxia Lin, Wenjie Li, Xing Li, Xiaodong Lin, Ning Li, Yan Ma, Lianjun Song, Xianqing Huang, Tiange Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tianlin WangCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.
Xiaoxia LinCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.
Wenjie LiCollege of Public Health, Zhengzhou University, Zhengzhou, 450000, China.
Xing LiCollege of Public Health, Zhengzhou University, Zhengzhou, 450000, China.
Xiaodong LinDepartment of Bioengineering, University of California, Riverside, CA, 92521, United States.
Ning LiCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.
Yan MaCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.
Lianjun SongCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.
Xianqing HuangCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.
Tiange LiCollege of Food Science and Technology, Henan Agricultural University, Zhengzhou, 450002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that is difficult to cure. The crucial pathogenic factors of IBD are mainly caused by the overexpression of pro-inflammatory cytokines and the disturbance of gut microbiota triggered by excessive reactive oxygen species (ROS). Herein, the resveratrol-embedded hollow cerium oxide composite nanomaterials with surface modified hyaluronic acid (Res-CeO

Indexed as

Gut microbiota modulationInflammatory bowel diseaseIntestinal mucosal immune homeostasis recoveryResveratrol-embedded hollow cerium oxideROS-Inflammation clearance

Identifiers

PMID41567735
PMCPMC12818119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.